-+ 0.00%
-+ 0.00%
-+ 0.00%

Aprogen Biologics lends KRW 29.1 billion to Ainsfac at 4.6% interest

PUBT·09/23/2026 07:29:01
Aprogen Biologics lends KRW 29.1 billion to Ainsfac at 4.6% interest
  • Aprogen Biologics’ board on Sept. 23 resolved to extend a cash loan to Ainsfac.
  • Loan set at KRW 29.1 billion, equal to 10.5% of equity based on year-end 2025 consolidated statements.
  • Facility priced at 4.6%, scheduled to run from Sept. 28, 2026 to Sept. 27, 2027.
  • Funding earmarked for strategic cash management to improve financial structure, with collateral to include Ainsfac investment interests.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aprogen Biologics Inc. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20260923800503), on September 23, 2026, and is solely responsible for the information contained therein.